This article outlines the pathology of acute coronary syndromes and clarifies the role of glycoprotein IIb/IIIa receptor inhibition in the emergency department setting.
Answers are grounded in this paper and cite their sources.
May guide ED ACS decisions on GP IIb/IIIa inhibitors; leaves open need for updated RCTs.
Acute coronary syndromes (ACS) are a major cause of morbidity and mortality in Western society. The commonest underlying pathology is the coronary atherosclerotic plaque complicated by thrombosis. Platelets play a central role. As the glycoprotein IIb/IIIa receptor is involved in the final step of platelet thrombus formation development and investigation of its blockage in ACS is at the fore. Initial hospital management of ACS occur in the ED setting. The present article outlines the above topics and clarifies the place of glycoprotein IIb/IIIa receptor inhibition in ED.
No takes yet. Share an insight, caveat, or question.
Deanne J Crosbie (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: